Biosimilars – Forecast – Endocrinology
In 2021, sales of insulins at the ex-manufacturer price level exceeded $20 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi will face increasing competition from insulin biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecasts for key reference brand insulins and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.
Table of contents
- Biosimilars - Forecast - Endocrinology
- Market forecast in the major pharmaceutical markets
- Major-market forecast: endocrinology biologics (insulin analogues)
- Terminology
- Overarching forecast assumptions
- Overview of insulin brands in forecast
- Overview of approved insulins
- Biosimilar entry assumptions for approved insulins
- Overview of insulin biosimilar assumptions
- Overview of insulin brands in forecast
- Drug-specific forecast assumptions
- Lantus
- Outlook for Lantus
- First major-market biosimilar entrants
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturing price assumptions
- Lantus sales forecast in the United States: 2021-2031
- Lantus sales forecast in the EU5: 2021-2031
- Lantus sales forecast in Japan: 2021-2031
- Toujeo
- Outlook for Toujeo
- First major-market biosimilar entrants
- Order of entry in the United States
- Order of entry in the EU5
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturing price assumptions
- Toujeo sales forecast in the United States: 2021-2031
- Toujeo sales forecast in the EU5: 2021-2031
- Humalog / Humalog Mix
- Outlook for Humalog / Humalog Mix
- First major-market biosimilar entrants
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturing price assumptions
- Humalog / Humalog Mix sales forecast in the United States: 2021-2031
- Humalog / Humalog Mix sales forecast in the EU5: 2021-2031
- Humalog / Humalog Mix sales forecast in Japan: 2021-2031
- NovoLog / NovoRapid and NovoMix
- Outlook for NovoLog / NovoRapid and NovoMix
- First major-market biosimilar entrants (NovoLog and NovoRapid)
- First major-market biosimilar entrants (NovoMix)
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturing price assumptions
- NovoLog / NovoRapid sales forecast in the United States: 2021-2031
- NovoLog / NovoRapid sales forecast in the EU5: 2021-2031
- NovoLog / NovoRapid sales forecast in Japan: 2021-2031
- NovoMix sales forecast in the United States: 2021-2031
- NovoMix sales forecast in the EU5: 2021-2031
- NovoMix sales forecast in Japan: 2021-2031
- Lantus
- Market forecast in the major pharmaceutical markets
Rashi Tiwari, Pharm.D., Associate Healthcare Research and Data Analyst, Biosimilars. Prior to joining Clarivate, Dr. Tiwari was a research associate in competitive intelligence at Vyuhgenics. She earned her doctorate in pharmacy from KLE College of Pharmacy in Belagavi, where she also interned as a clinical research coordinator at KLE’s Dr. Prabhakar Kore Hospital.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.